Indivior gets favorable ruling on Suboxone Film patent

4 June 2016

UK based Indivior (LSE: INDV) on Friday received a favorable ruling in the District Court of Delaware in the ANDA litigation against Actavis Laboratories (now an Allergan [NYSE: AGN] company) and Par Pharmaceutical (part of the Endo International group) relating to Suboxone (buprenorphine and naloxone) its treatment for opioid addiction.

Shares in Indivior, which was spun out from, Reckitt Benckiser in 2014, were up 36% at 235.1 pence Friday afternoon, having risen to as high as 247.9 pence.

The ruling confirms Indivior’s belief in the validity and enforceability of its Suboxone Film patent portfolio and provides the business with substantially greater certainty about the nearer-term outlook.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK